The National  Memo Logo

Smart. Sharp. Funny. Fearless.

Monday, December 09, 2019 {{ new Date().getDay() }}

To be American is a wonderful thing most of the time. There are moments, however, when it is downright humiliating. Can you imagine a more pitiful scene than a busload of Americans traveling 815 miles from Minneapolis to a Walmart in London, Ontario, Canada, to buy insulin at a 10th — a 10th! — of the price charged in the United States?

Dollar-wise, the difference is not modest. In the U.S., one vial of insulin costs around $300. In Canada, it’s $30.

From 2012 to 2016, drugmakers nearly doubled the U.S. price of a medication that was invented almost a century ago. Type 1 diabetics saw their yearly insulin costs soar from about $2,900 to about $5,700. Deb Souther, a woman making the trip, said that even with insurance she’s been paying $700 a month for this essential medicine.

We’re not talking about a take-it-or-leave-it product. These are not lawn chairs or T-shirts, which, in any case, are manufactured by numerous companies competing for your consumer dollar. We are talking about insulin, a lifesaving drug for diabetics produced by three companies.

We’re talking about lives. Diabetics who’ve been cutting back on their prescribed insulin because they couldn’t afford it have been dying as a result. One was Alec Smith, who, after aging out of his mother’s health insurance plan when he was 26, rationed his insulin, assuming he could survive until he saved money to buy what he needed. He was found dead in his apartment.

We might ask how the pharmaceutical industry gets away with extorting Americans with its your-money-or-your life demands. The answer is that other countries negotiate with the drugmakers to set reasonable prices. Republicans in Washington, on the other hand, have served the American public to them on a silver platter.

The American government is not allowed to negotiate, with one notable exception. The Department of Veterans Affairs obtains deep discounts on drugs through direct negotiation. By contrast, the Republicans’ Medicare drug benefit of 2003 specifically bans the U.S. government from bargaining on prices for medications.

If Medicare Part D, the drug benefit, were to pay prescription prices similar to what the VA pays, Medicare would enjoy a savings of about 44 percent on the top 50 oral drugs, according to an analysis published in JAMA Internal Medicine. In dollar terms, the savings in 2016 would be over $14 billion.

When President Trump campaigned in 2016, he vowed to have the government negotiate on Medicare drug price. After the election, the promise vanished.

Right before the 2018 midterms, Trump suggested a modest plan whereby Medicare Part B — the part covering drugs administered by doctors and hospitals — would use an International Pricing Index as a benchmark for setting prices. With a presidential election looming, Trump seems to be reviving that kind of talk again.

Of course, this is just more pre-election trickery. Even so, some Republicans expressed alarm at the very idea, calling it government “price controls.” They apparently prefer that drug companies control the prices.

Trump’s secretary of health and human services happens to be Alex Azar, a former Eli Lilly executive. Lilly’s Humalog pen is seen as one of the villains in insulin price gouging.

Azar has diverted blame to socialism. “The American senior and the American patient have been too long been asked to overpay for drugs to subsidize the socialist systems of Europe,” Azar charged.

And who’s been asking — no, forcing — the American people to pay so much? The drug industry and it’s (mostly) Republican enforcers.

Americans lining up at a Canadian Walmart prescription drug counter to buy lifesaving drugs at a 10th the U.S. price must have been a pathetic sight. Only a change in Washington, starting with the White House, will end the outrage.


Start your day with National Memo Newsletter

Know first.

The opinions that matter. Delivered to your inbox every morning

New Poll Reveals Problems For Trump--And His Party

Image via Twitter

A year after former President Donald Trump left the White House and Joe Biden was sworn in as president of the United States, Trump continues to have considerable influence in the Republican Party. Sen. Lindsey Graham of South Carolina, a former Trump critic turned Trump sycophant, recently told Fox News that having a “working relationship” with Trump must be a litmus test for anyone in a GOP leadership role in Congress. But an NBC News poll, conducted in January 14-18, 2022, finds that many Republican voters identify as Republicans first and Trump supporters second.

Analyzing that poll in the New York Times on January 21, reporters Leah Askarinam and Blake Hounshell, explain, “Buried in a new survey published today is a fascinating nugget that suggests the Republican Party may not be as devoted to Trump as we’ve long assumed. Roughly every month for the last several years, pollsters for NBC News have asked: ‘Do you consider yourself to be more of a supporter of Donald Trump or more of a supporter of the Republican Party?’ Over most of that time, Republicans have replied that they saw themselves as Trump supporters first.”

Keep reading... Show less

Ivanka Trump Testifying To January ^ Committee Is Vital

Image via @Huffington Post

As House Speaker Nancy Pelosi’s select committee on the January 6, 2021 insurrection moves along, it is examining Ivanka Trump’s actions that day — especially the former White House senior adviser urging her father, then- President Donald Trump, to call off his supporters when the U.S. Capitol Building was under attack. This week, Ivanka Trump’s importance to the committee is the focus of a column by liberal Washington Post opinion writer Greg Sargent and an article by blogger Marcy Wheeler.

Sargent notes that the committee’s “new focus on Ivanka Trump” shows that it “is developing an unexpectedly comprehensive picture of how inextricably linked the violence was to a genuine plot to thwart a legitimately elected government from taking power.”

Keep reading... Show less
{{ }}